HONG KONG, Mar 6, 2025 - (ACN Newswire via SeaPRwire.com) - Hong Kong Science and Technology Parks Corporation (HKSTP) joined the Hong Kong Trade Development Council (HKTDC) in highlighting achievements of 24 tech companies and corporations at the Mobile World Congress (MWC) in Barcelona, marking it the largest delegation to date joining the world's biggest mobile industry event.The Hong Kong Tech Pavilion continues its journey overseas from recent appearance at Consumer Electronics Show (CES) in Las Vegas and engages the premises of Europe, covering the latest solutions in key sectors including Advanced Electronics & Robotics; AI & Data; and Digital Transformation. Ranging from AI-integrated products to automation services, these technological excellence brewed optimism in extending to new frontiers, and gain traction from industry leaders, potential partners, and inspired investors. (Please refer to Appendix 1 for the full list of participants.)A partnership agreement signed between HKSTP and 22@Network Barcelona, and a Memorandum of Understanding signed between HKTDC and Barcelona City Council, both witnessed by Prof Sun Dong, Secretary for Innovation, Technology and Industry Bureau (ITIB) of HKSAR Government, will be urging conversations in promoting collective efforts between the cities for a sustainable I&T future.Albert Wong, CEO of HKSTP, commented: "The world's premier mobile event makes an unrivalledopportunity to forge impactful connections – an important stage for each local tech company to play a role in the European and global markets and accelerate the adoption of transformative solutions. We look forward with excitement to witnessing new opportunities for innovation on both sides emerge at this year's conference."Iris Wong, Director of Merchandise Trade and Innovation & External Relations of HKTDC added: “The HKTDC is committed to showcasing Hong Kong’s dynamic technological prowess on the global stage. We are proud to present 24 outstanding Hong Kong start-ups and tech ventures at the Mobile World Congress, an important global arena showcasing the latest mobile communications advances. Moreover, we are happy to renew our partnership with Barcelona City Council and continuously strengthen cooperation in promoting trade and investment between the two cities. The HKTDC also continues to work closely with the city council to help Hong Kong tech start-ups gain exposure in the Spanish market"As one of the top emerging startup ecosystems, Hong Kong ranks third global after Madrid and Barcelona, and companies from the EU make up the largest foreign business community in Hong Kong, totalling 1,640 according to government data in 2024, and Technology is highly active contributing to this figure, suggesting spotlight in I&T collaborations between the regions is encouraged. Sharing the notion, HKSTP will be joining Hong Kong Economic and Trade Office, London (London ETO), Invest Hong Kong (InvestHK), and the Office for Attracting Strategic Enterprises (OASES) to co-organise a seminar in London, following further on the traction for potential investors, partners, and high-calibre talents to thrive in Hong Kong.Photo download: https://tinyurl.com/2v93bpcrPhoto 1: Hong Kong Tech Pavilion saw the presence of (from left) Paula Kant, Head of Investment Promotion of InvestHK; Chris Lo, Regional Director, Europe, Central Asia & Israel of HKTDC; Albert Wong, CEO of HKSTP; Susana Prado, President of 22@Network Barcelona; Shirley Yung, Special Represenattive for HK Economic & Trade Affairs to the European Union, Brussels ETO; Prof. Sun Dong, Secretary for Innovation, Technology and Industry of HKSAR Government; Jordi Valls Riera, Deputy Mayor of Barcelona City Council; Iris Wong, Director of Merchandise Trade and Innovation & External Relations of HKTDC; Rocky Cheng, CEO of Cyberport; and Whitney Chan, Senior Systems Manager of Digital Policy Office of HKSAR Government. Photo 2: MoU signed between the HKTDC and Barcelona City Council was represented by Iris Wong, Director of Merchandise Trade and Innovation & External Relations of HKTDC (left) and Jordi Valls Riera, Deputy Mayor of Barcelona City Council (right), and witnessed by Prof. Sun Dong, Secretary for Innovation, Technology and Industry of HKSAR Government (middle). Photo 3: A Partnership agreement signed by Albert Wong, CEO of HKSTP (left in front) and Susana Prado, President of 22@Network Barcelona (right in front) was witnessed by Prof. Sun Dong, Secretary for Innovation, Technology and Industry of HKSAR Government (left in the back) and Jordi Valls Riera, Deputy Mayor of Barcelona City Council (right in the back) in forming an alliance to foster growth of both the I&T communities. Photo 4-5: Derek Chim, Head of Startups Ecosystem and Development of HKSTP (first on the left of Photo 4) joined in sharing Hong Kong’s I&T ecosystem at the 4YFN25, an occasion that connects international innovators, and celebrates achievement and aim to “Create Better.”Photo 6: 24 Hong Kong tech companies and corporations at Mobile World Congress 2025 Barcelona, Spain. Photo 7-10: Showcases of Hong Kong tech companies engaging the local audience.Appendix 1: List of 24 tech companies at the Hong Kong Tech Pavilion including 18 from HKSTP ecosystem (by category):No.CategoryCompany Name1Advanced Electronics & RoboticsAltai Technologies Limited2Arwin Technology Limited3eSIX Limited4Robocore Technology Limited5SMiT Holdings (HK) Limited6Vista Innotech Limited7AI & DataAIqua Corporation Limited8D-Engraver Limited9Palette Space Limited10Solos Technology Limited11Electrical and Mechanical Services Department, HKSAR Government *12Maphive Technology Limited *13MTR Corporation Limited *14Digital TransformationAnimae Technologies Limited15Blue Pin (HK) Limited16Full Nature Farms (Hong Kong) Limited17GoGoChart Technology Limited18Medmind Technology Limited19Meta Mirror Technology Limited *20Pantheon Lab Limited21Preface Technopreneur Limited *22Syngular Technology Limited23Startup EcosystemHong Kong Applied Science and Technology Research Institute Company Limited (ASTRI)24Invest Hong Kong (InvestHK) *Note:- Non-HKSTP park companies marked with (*).About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 as a thriving I&T ecosystem grooming 14 unicorns, more than 15,000 research professionals and over 2,200 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. The growing ecosystem serves at an international I&T hub in Asia, offers comprehensive support including R&D infrastructure, investment expertise, partnership networks, talent traction and more, in accelerating ideation, and commercialising innovation for technology ventures, all with the I&T journey built around key locations across Hong Kong and branched towards the GBA and further to continuously contribute to the development of I&T making a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org. About Hong Kong Trade Development CouncilThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Media Contact: Hong Kong Science and Technology Parks CorporationSam YanTel: +852 2629 6743Email: sam.yan@hkstp.orgThe Hoffman AgencyDaphne ChanTel: +852 5960 7926Email: dchan@hoffman.comHong Kong Trade Development CouncilKaty WongTel: +852 2584 4524Email: katy.ky.wong@hktdc.comRaconteurBetsy TseTel: +852 9742 7338Email: betsytse@reconteur.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters– The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities– T2DM phase 3 data readout is expected to be announced in the first half of 2025ROCKVILLE, MD and SHENZHEN, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. The publication reports results of the randomized, placebo-controlled 12-week study to assess efficacy, safety and tolerability of HTD1801 compared to placebo in patients with T2DM. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 12 with HTD1801 versus placebo. A majority of patients treated with HTD1801 achieved target HbA1c

CardCash Platform Provides Cost-Reduction Strategy for High-Demand Sports Tickets and Merchandise Ahead of 2025 Major League Baseball (MLB) SeasonPlatform Supports Savings on Popular Sports Retailers Including StubHub, Nike, Adidas, Under Armour, Dick's Sporting Goods, and FanaticsSchaumburg, Illinois, Mar 5, 2025 - (ACN Newswire via SeaPRwire.com) - Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the expansion of its CardCash.com platform into the high-margin sports retail sector, offering consumers smart saving solutions for sports fans to save on tickets, apparel and game-day essentials as part of the Company’s strategic growth initiative for 2025.With the 2025 MLB season getting underway, fans are facing rising costs for tickets, gear, and game-day essentials. The average cost of attending a baseball game has climbed to $152 for a family of four, with premium seats seeing increases as high as 38.8%. But CardCash.com, a leading secondary gift card exchange operated by Giftify, is stepping up to help fans save.By using discounted gift cards from StubHub, Nike, Adidas, Under Armour, Dick’s Sporting Goods, and Fanatics, families can cut costs on tickets, jerseys, and game-day snacks.For example, a family of four heading to a Yankees game this season, their tickets alone would cost over $300, but by paying with StubHub gift cards purchased at CardCash.com at an 11% discount, they save over $30. Grabbing team gear from MLB Shop? That's another 11% saved.Making Baseball More Affordable“With rising ticket prices, fans are looking for ways to save without missing out on their favorite teams,” said Carol Rosenblum, Marketing Manager at CardCash.com. “By using our discounted gift cards, baseball lovers can cut costs by 10-20%, whether they’re buying tickets, upgrading their game-day outfits, or picking up tailgating gear.”Spring Cleaning: Turn Unused Gift Cards into Game-Day CashThe CardCash.com platform offers a comprehensive solution for sports fans: not only can they purchase discounted gift cards to save on upcoming expenses, but they can also monetize unused gift cards by exchanging them for cash or store credit—creating a complete financial ecosystem for sports enthusiasts. Just as fans engage in spring cleaning around their homes, CardCash encourages them to clear out their wallets and drawers of forgotten gift cards and transform that untapped value into memorable sports experiences.“As MLB teams welcome fans back to stadiums across the nation, this is the perfect time for people to check their wallets, trade in unused gift cards, and put those funds toward experiences they’ll actually enjoy,” said Ketan Thakker, CEO of Giftify, Inc. “Why let old gift cards go to waste when they can help get you to the ballpark? This sports fan initiative represents a key component of our 2025 growth strategy to penetrate high-frequency consumer spending categories while building recurring engagement with our platform.”About Giftify, Inc.Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.Forward-Looking StatementsPress Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.Investors Contacts:IR@giftifyinc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."About MEndoBMicreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.About MicreosMicreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.For more information, visit www.micreos.com.About Northway BiotechNorthway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.For more information, please visit www.northwaybiotech.com.Micreos Contact:Matt ReganCEO and Board member, Micreos Pharmaceutical AGm.regan@micreos.comNorthway Biotech Contact:Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comContact InformationVladas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comSOURCE: Northway Biotech Copyright 2025 ACN Newswire via SeaPRwire.com.

LONDON, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - In a landmark event, the United Kingdom will host the Global Anti-Scam Summit (GASS) London 2025, bringing together an unprecedented number of policymakers, industry leaders, and cybersecurity experts. This summit, organized by the UK Home Office, Global Anti-Scam Alliance (GASA), Cifas, and Euroconsumers, is set to be the most significant anti-scam event to date, with a focus on forging global partnerships to address the rampant rise of online scams, which last year cost the global economy nearly US$1.03 trillion.Unveiling Global Strategies Against ScamsThe summit will kick off with keynote speeches from top international figures, including The Rt Hon Lord Hanson of Flint, who will outline the UK's initiatives and the collaborative efforts needed to combat this global menace. Discussions will focus on enhancing international cooperation, harmonizing scam prevention efforts, and leveraging technology to protect consumers worldwide.Panel discussions on the first day will explore the urgent need for coordinated global action. Sessions will dive into the human cost of scams, share international lessons in scam prevention, and highlight the role of public-private partnerships in advancing fraud legislation and industry best practices. The main focus of the event is to foster cross-border and -sector collaborations.Industry Leaders to Drive Technological InnovationsThe summit will also feature contributions from tech giants and financial institutions, focusing on how cutting-edge technologies like AI can be utilized to thwart scammers effectively. Industry leaders will discuss the creation of the Global Signal Exchange, an innovative platform aimed at enhancing data sharing across borders to better track and prevent scams.Day two of GASS London 2025 will be dedicated to solutions-focused workshops and breakout sessions. Experts will present the latest advancements in scam detection and prevention, from deepfake recognition to strategies for securing digital identities. Interactive discussions will enable participants to share insights and develop actionable strategies for protecting consumers globally, such as the GASA recommendation that every country should have a dedicated national anti-scam centre.The event agenda and attendance tickets are available here: https://www.gasa.org/gass-2025-londonThe summit will look to solidify commitments from attending public and private organizations and set a roadmap for international cooperation through 2026 and beyond.GASS London 2025 is a call to action for every stakeholder in the fight against online fraud. It offers a unique opportunity to join forces with global leaders and take a stand against the cyber threats that impact millions of lives each year.Selected speakers include:Aad Lensen, Jeroen Niessen, and Ruben van Well, Dutch PoliceAndrei Skorobogatov, Home OfficeAngelique Miet, European CommissionBen Donaldson, UK FinanceDr Elizabeth Carter, Kingston University LondonEls Bruggeman, EuroconsumersHedwige Nuyens, International Banking Federation (IBFed)Henriette Bongers, FraudeHelpdesk.nlJayde Richmond, Australian National Anti-Scam CentreJean-Jacques Sahel, GoogleJorij Abraham, GASAKate Griffin, Aspen InstituteKitboga, YouTube ScambaiterLaura Kankaala, F-SecureLucia Harris, Match GroupLuke Reynolds, MastercardLynette Owens, Trend MicroMike Haley, CifasNatalie Black, OFCOMNathaniel Gleicher, MetaThe event agenda and attendance tickets are available here: https://www.gasa.org/gass-2025-londonContact InformationSam RogersMarketing Director, Global Anti-Scam Alliancesam.rogers@gasa.org+31 (0) 645 130 670Hayley PatersonPress & PR Manager, Cifashayley.paterson@cifas.org.ukRelated VideoSOURCE: Global Anti-Scam AllianceRelated Documents: Global State of Scams Report - 2024.pdfState of Scams in the United Kingdom Report - 2024.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics (GA) today announced the strategic acquisition of North Point Defense, Inc. (NPD), a leading provider of Signals Intelligence (SIGINT) exploitation software and sensor integration, by General Atomics Integrated Intelligence, Inc. (GA-III), formerly known as General Atomics Commonwealth Computer Research, Inc. This acquisition enhances GA's capabilities in the rapidly evolving SIGINT field, positioning the company to deliver advanced ISR solutions for air, sea, ground, and space platforms.The new Quadratix enterprise will bond GA's large software workforce and extensive suite of systems under a unified umbrella, merging solutions for: From concept to deployment, NPD delivers AI/ML-based autonomous signal processing and data dissemination solutions providing real-time actionable intelligence, supporting tactical and national mission priorities. "Joining GA represents an incredible opportunity to enhance our impact in delivering cutting-edge SIGINT solutions in support of national and tactical users," said Bruce Benenati, President of NPD. "As part of a mission-focused organization with a proven track-record in tactical intelligence across the DoD and IC, we can accelerate innovation and deployment at scale. The integration gives our team access to unmatched operational expertise, resources, and a broader customer base. Together, we are poised to deliver even greater capabilities to those who depend on us in the field."GA-III is committed to providing a comprehensive suite of "out-of-the-box" hardware and software tools to meet mission requirements and expand the innovative intelligence capabilities within the GA group of companies. "The integration of NPD technologies into a division of GA-III is a strategic shift, enhancing GA's ability to innovate rapidly and provide greater value to customers with end-to-end ISR solutions that are more efficient, effective, and technologically advanced." said Brian Ralston, President of GA-III.Baird served as the exclusive financial adviser and Miles & Stockbridge acted as legal counsel to North Point Defense on the transaction.About General Atomics and General Atomics Integrated IntelligenceGeneral Atomics is a defense and diversified technologies company, founded in 1955 as a division of General Dynamics and acquired by the Blue family in 1986. GA and affiliates operate on five continents, and produce unmanned aircraft and airborne sensor systems, satellite surveillance, high power laser, hypervelocity projectile, and power conversion systems. GA is a leader in nuclear fusion research, next-generation nuclear fission and advanced materials technologies. The company occupies 8+ million square feet of engineering, laboratory and manufacturing facilities and comprises over 13,000 employees.GA-III's capabilities include spatio-temporal data management, advanced analytics, visualization tools, and computer vision, alongside AI/ML-enabled automated target recognition services. These capabilities support a wide range of national, tactical, and commercial/international applications, leveraging both commercial cloud and edge-based computing solutions and are fully integrated with GA Aeronautical Systems' unmanned aircraft and airborne sensor systems.Media Contact: https://www.ga.com/general-business-inquiriesContact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.